$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
卵巢癌用药尼拉帕尼(尼拉帕利)服用方法
2025-10-19 11:44:20
Check Details
研究发现辅助生殖技术不会增加患卵巢癌的风险
2025-10-19 11:44:20
Check Details
奥拉帕利吃一年要多少钱?
2025-10-19 11:44:20
Check Details
奥拉帕利靶向药的价格
2025-10-19 11:44:20
Check Details
晚期卵巢癌治疗新选择-奥拉帕利
2025-10-19 11:44:20
Check Details
奥拉帕利怎么买?
2025-10-19 11:44:20
Check Details
抗癌药奥拉帕利在国内上市了吗?
2025-10-19 11:44:20
Check Details
靶向药奥拉帕利在医保范围内吗?
2025-10-19 11:44:20
Check Details
他比特定治疗卵巢癌的效果
2025-10-19 11:44:20
Check Details
卵巢癌靶向治疗药物尼拉帕利效果如何?
2025-10-19 11:44:20
Check Details
尼拉帕利2020价格
2025-10-19 11:44:20
Check Details
尼拉帕利是哪里产的?
2025-10-19 11:44:20
Check Details
1
2
...
872
873
874
875
876
877
878
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
2
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
3
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
4
Tucatinib HER2 TKI: With Trastuzumab + Capecitabine, Diarrhea and Hepatotoxicity Monitoring
5
Pemigatinib for FGFR2-Rearranged Cholangiocarcinoma: Eligibility, Response Limits, Hyperphosphatemia and Ocular Monitoring
6
Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs
7
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
8
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
9
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
10
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
11
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
12
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management